What is Bio Rad Labs Inc's earnings per share (EPS)?

Bio Rad Labs Inc (BIO) reported diluted earnings per share of $27.85 for fiscal year 2025. This represents a 142.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio Rad Labs Inc Financials

BIO

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Bio Rad Labs Inc (BIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 59/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Bio Rad Labs Inc has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 26/100, suggesting thin profitability after operating expenses. This is down from 10.5% the prior year.

Growth

Bio Rad Labs Inc's revenue grew a modest 0.7% year-over-year to $2.6B. This slow but positive growth earns a score of 34/100.

Leverage

Bio Rad Labs Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.62, Bio Rad Labs Inc holds $5.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Bio Rad Labs Inc has a free cash flow margin of 14.5%, earning a moderate score of 61/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Bio Rad Labs Inc's ROE of 10.2% shows moderate profitability relative to equity, earning a score of 34/100. This is up from -28.1% the prior year.

Altman Z-Score Safe

3.06

Bio Rad Labs Inc scores 3.06, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

Bio Rad Labs Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

0.70x

For every $1 of reported earnings, Bio Rad Labs Inc generates $0.70 in operating cash flow ($532.2M OCF vs $759.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

1.0x

Bio Rad Labs Inc earns $1.0 in operating income for every $1 of interest expense ($47.2M vs $49.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.6B

YoY+0.7%

5Y CAGR+0.3%

10Y CAGR+2.5%

Bio Rad Labs Inc generated $2.6B in revenue in fiscal year 2025. This represents an increase of 0.7% from the prior year.

EBITDA

$212.6M

YoY-49.5%

5Y CAGR-17.6%

10Y CAGR-3.3%

Bio Rad Labs Inc's EBITDA was $212.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.5% from the prior year.

Net Income

$759.9M

YoY+141.2%

5Y CAGR-27.6%

10Y CAGR+21.4%

Bio Rad Labs Inc reported $759.9M in net income in fiscal year 2025. This represents an increase of 141.2% from the prior year.

EPS (Diluted)

$27.85

YoY+142.6%

5Y CAGR-26.1%

10Y CAGR+22.3%

Bio Rad Labs Inc earned $27.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 142.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$374.6M

YoY+29.4%

5Y CAGR-4.7%

10Y CAGR+17.6%

Bio Rad Labs Inc generated $374.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.4% from the prior year.

Cash & Debt

$529.8M

YoY+8.5%

5Y CAGR-4.4%

10Y CAGR+1.5%

Bio Rad Labs Inc held $529.8M in cash against $1.2B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

51.9%

YoY-1.9pp

5Y CAGR-4.6pp

10Y CAGR-3.7pp

Bio Rad Labs Inc's gross margin was 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.

Operating Margin

1.8%

YoY-8.7pp

5Y CAGR-14.7pp

10Y CAGR-6.4pp

Bio Rad Labs Inc's operating margin was 1.8% in fiscal year 2025, reflecting core business profitability. This is down 8.7 percentage points from the prior year.

Net Margin

29.4%

YoY+101.3pp

5Y CAGR-120.4pp

10Y CAGR+24.0pp

Bio Rad Labs Inc's net profit margin was 29.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 101.3 percentage points from the prior year.

Return on Equity

10.2%

YoY+38.3pp

5Y CAGR-28.4pp

10Y CAGR+5.8pp

Bio Rad Labs Inc's ROE was 10.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 38.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$275.6M

YoY-6.9%

5Y CAGR+4.8%

10Y CAGR+3.6%

Bio Rad Labs Inc invested $275.6M in research and development in fiscal year 2025. This represents a decrease of 6.9% from the prior year.

Share Buybacks

$295.5M

YoY+45.1%

5Y CAGR+24.2%

Bio Rad Labs Inc spent $295.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.1% from the prior year.

Capital Expenditures

$157.6M

YoY-4.8%

5Y CAGR+7.7%

10Y CAGR+3.5%

Bio Rad Labs Inc invested $157.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 4.8% from the prior year.

BIO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.6B+0.7%	$2.6B-3.9%	$2.7B-4.7%	$2.8B-4.1%	$2.9B+14.8%	$2.5B
Cost of Revenue	$1.2B+4.7%	$1.2B-4.6%	$1.2B+0.8%	$1.2B-3.9%	$1.3B+16.0%	$1.1B
Gross Profit	$1.3B-2.8%	$1.4B-3.4%	$1.4B-9.0%	$1.6B-4.3%	$1.6B+13.9%	$1.4B
R&D Expenses	$275.6M-6.9%	$295.9M+19.6%	$247.4M-3.7%	$256.9M-1.4%	$260.6M+19.7%	$217.8M
SG&A Expenses	$844.3M+3.7%	$814.0M-3.3%	$841.7M+1.7%	$827.8M-5.6%	$877.1M+9.8%	$798.8M
Operating Income	$47.2M-82.5%	$269.0M-20.4%	$337.8M-30.0%	$482.6M-3.5%	$500.3M+18.8%	$421.3M
Interest Expense	$49.0M+0.2%	$48.9M-1.0%	$49.4M+29.7%	$38.1M+2356.5%	$1.6M-92.9%	$21.9M
Income Tax	$235.6M+147.3%	-$498.3M-134.2%	-$212.8M+80.2%	-$1.1B-190.1%	$1.2B+8.2%	$1.1B
Net Income	$759.9M+141.2%	-$1.8B-189.4%	-$637.3M+82.4%	-$3.6B-185.3%	$4.3B+11.5%	$3.8B
EPS (Diluted)	$27.85+142.6%	$-65.36-199.5%	$-21.82+82.1%	$-121.79-186.5%	$140.83+11.4%	$126.47

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$693.2M+6.2%	$653.0M+0.2%	$651.6M+11.3%	$585.4M-12.3%	$667.5M+2.7%	$649.7M+1.8%	$638.5M+4.5%	$610.8M
Cost of Revenue	$348.0M+12.4%	$309.6M+1.1%	$306.3M+9.6%	$279.4M	N/A	$293.8M+3.7%	$283.4M-0.5%	$284.9M
Gross Profit	$345.2M+0.5%	$343.4M-0.6%	$345.3M+12.8%	$306.0M-10.5%	$342.0M-3.9%	$355.9M+0.2%	$355.1M+9.0%	$325.9M
R&D Expenses	$70.3M-1.4%	$71.3M+17.9%	$60.5M-17.7%	$73.5M	N/A	$91.0M+54.5%	$58.9M-11.3%	$66.4M
SG&A Expenses	$221.0M+6.9%	$206.8M-0.4%	$207.7M-0.5%	$208.8M	N/A	$200.4M+2.9%	$194.7M-9.4%	$214.9M
Operating Income	-$118.9M-282.1%	$65.3M-15.3%	$77.1M+225.3%	$23.7M	N/A	$64.5M-36.5%	$101.5M+127.6%	$44.6M
Interest Expense	$12.1M-1.6%	$12.3M-2.4%	$12.6M+5.0%	$12.0M	N/A	$12.1M-1.6%	$12.3M0.0%	$12.3M
Income Tax	$209.2M+334.5%	-$89.2M-192.7%	$96.2M+395.9%	$19.4M	N/A	$208.4M+133.6%	-$620.8M-679.1%	$107.2M
Net Income	$720.0M+310.6%	-$341.9M-207.6%	$317.8M+396.6%	$64.0M+108.9%	-$715.8M-209.6%	$653.2M+130.2%	-$2.2B-664.1%	$383.9M
EPS (Diluted)	N/A	$-12.70-208.8%	$11.67+409.6%	$2.29+109.0%	$-25.57-209.6%	$23.34+130.6%	$-76.26-667.0%	$13.45

BIO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.6B+12.9%	$9.4B-23.9%	$12.3B-8.9%	$13.5B-24.1%	$17.8B+37.2%	$13.0B
Current Assets	$2.9B-4.1%	$3.0B-0.6%	$3.0B-3.5%	$3.2B+58.7%	$2.0B-7.0%	$2.1B
Cash & Equivalents	$529.8M+8.5%	$488.1M+20.9%	$403.8M-7.0%	$434.2M-7.8%	$470.8M-28.9%	$662.2M
Inventory	$740.7M-2.5%	$760.0M-2.6%	$780.5M+8.5%	$719.3M+25.7%	$572.2M-8.0%	$622.3M
Accounts Receivable	$460.6M+1.8%	$452.5M-7.5%	$489.0M-1.1%	$494.6M+16.8%	$423.5M+1.0%	$419.4M
Goodwill	$579.8M+41.2%	$410.5M-0.7%	$413.6M+1.7%	$406.5M+17.0%	$347.3M+19.0%	$291.9M
Total Liabilities	$3.1B+11.7%	$2.8B-21.4%	$3.6B-8.5%	$3.9B-5.5%	$4.1B+33.0%	$3.1B
Current Liabilities	$517.0M+10.5%	$467.8M-10.5%	$522.8M-8.1%	$568.7M-16.5%	$680.9M+7.8%	$631.5M
Long-Term Debt	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+11291.5%	$10.5M-14.2%	$12.3M
Total Equity	$7.5B+13.5%	$6.6B-24.8%	$8.7B-9.1%	$9.6B-29.7%	$13.7B+38.4%	$9.9B
Retained Earnings	$8.2B+10.2%	$7.4B-19.9%	$9.3B-6.4%	$9.9B-26.8%	$13.5B+45.9%	$9.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$10.6B+9.1%	$9.7B-5.1%	$10.2B+7.2%	$9.5B+1.7%	$9.4B-11.7%	$10.6B+9.4%	$9.7B-23.2%	$12.6B
Current Assets	$2.9B+2.3%	$2.8B+1.1%	$2.8B-7.4%	$3.0B+0.2%	$3.0B-0.8%	$3.1B0.0%	$3.1B-0.2%	$3.1B
Cash & Equivalents	$529.8M+33.9%	$395.8M+7.2%	$369.3M-29.2%	$521.4M+6.8%	$488.1M+18.9%	$410.4M+0.9%	$406.9M-6.1%	$433.3M
Inventory	$740.7M-5.4%	$783.2M-2.0%	$798.8M+1.1%	$790.1M+4.0%	$760.0M-5.5%	$804.3M+0.1%	$803.7M+2.6%	$783.4M
Accounts Receivable	$460.6M-0.9%	$464.7M-1.1%	$469.9M+10.6%	$424.7M-6.1%	$452.5M-2.0%	$461.9M+3.7%	$445.5M+0.2%	$444.8M
Goodwill	$579.8M+0.2%	$578.7M-0.5%	$581.6M+40.3%	$414.6M+1.0%	$410.5M-1.1%	$415.1M+0.7%	$412.1M-0.2%	$412.8M
Total Liabilities	$3.1B+5.5%	$3.0B-4.1%	$3.1B+8.4%	$2.8B+1.9%	$2.8B-10.3%	$3.1B+7.1%	$2.9B-18.2%	$3.6B
Current Liabilities	$517.0M-1.0%	$522.3M-4.8%	$548.9M+8.3%	$506.6M+8.3%	$467.8M-6.1%	$497.9M+2.3%	$487.0M+4.5%	$466.2M
Long-Term Debt	$1.2B0.0%	$1.2B0.0%	$1.2B0.0%	$1.2B0.0%	$1.2B0.0%	$1.2B0.0%	$1.2B0.0%	$1.2B
Total Equity	$7.5B+10.6%	$6.7B-5.5%	$7.1B+6.7%	$6.7B+1.7%	$6.6B-12.3%	$7.5B+10.5%	$6.8B-25.1%	$9.1B
Retained Earnings	$8.2B+9.7%	$7.5B-4.4%	$7.8B+4.2%	$7.5B+0.9%	$7.4B-8.8%	$8.1B+8.7%	$7.5B-22.5%	$9.6B

BIO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$532.2M+16.9%	$455.2M+21.4%	$374.9M+92.8%	$194.4M-71.0%	$669.5M+14.4%	$585.0M
Capital Expenditures	$157.6M-4.8%	$165.6M+5.7%	$156.7M+38.9%	$112.8M-15.7%	$133.7M+23.2%	$108.6M
Free Cash Flow	$374.6M+29.4%	$289.6M+32.7%	$218.2M+167.4%	$81.6M-84.8%	$535.7M+12.4%	$476.4M
Investing Cash Flow	-$189.7M-18.4%	-$160.2M-893.1%	$20.2M+101.7%	-$1.2B-51.4%	-$797.4M-1040.8%	-$69.9M
Financing Cash Flow	-$283.2M-29.4%	-$218.8M+48.6%	-$425.6M-143.7%	$973.6M+1856.5%	-$55.4M+89.4%	-$523.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$295.5M+45.1%	$203.6M-52.5%	$428.7M+98.7%	$215.7M+331.4%	$50.0M-50.0%	$100.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$164.9M+36.4%	$120.9M+3.8%	$116.5M-10.3%	$129.9M+4.6%	$124.2M-24.1%	$163.6M+67.6%	$97.6M+39.8%	$69.8M
Capital Expenditures	$45.8M+44.5%	$31.7M-30.6%	$45.7M+32.8%	$34.4M-19.8%	$42.9M+6.7%	$40.2M-5.0%	$42.3M+5.2%	$40.2M
Free Cash Flow	$119.1M+33.5%	$89.2M+26.0%	$70.8M-25.9%	$95.5M+17.5%	$81.3M-34.1%	$123.4M+123.1%	$55.3M+86.8%	$29.6M
Investing Cash Flow	-$34.2M+20.5%	-$43.0M+62.7%	-$115.4M-4079.3%	$2.9M+109.5%	-$30.5M+45.2%	-$55.7M-80.3%	-$30.9M+28.3%	-$43.1M
Financing Cash Flow	$3.3M+106.3%	-$52.5M+61.5%	-$136.3M-39.5%	-$97.7M-272.9%	-$26.2M+72.7%	-$96.0M+0.6%	-$96.6M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$53.4M-61.9%	$140.2M+37.6%	$101.9M	$0-100.0%	$97.9M-3.1%	$101.0M+2048.9%	$4.7M

BIO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	51.9%-1.9pp	53.7%+0.3pp	53.4%-2.5pp	55.9%-0.1pp	56.0%-0.4pp	56.5%
Operating Margin	1.8%-8.7pp	10.5%-2.2pp	12.7%-4.6pp	17.2%+0.1pp	17.1%+0.6pp	16.6%
Net Margin	29.4%+101.3pp	-71.9%-48.0pp	-23.9%+105.6pp	-129.4%-275.0pp	145.6%-4.3pp	149.8%
Return on Equity	10.2%+38.3pp	-28.1%-20.8pp	-7.3%+30.4pp	-37.7%-68.8pp	31.1%-7.5pp	38.6%
Return on Assets	7.2%+26.9pp	-19.7%-14.5pp	-5.2%+21.7pp	-26.9%-50.8pp	23.9%-5.5pp	29.4%
Current Ratio	5.62-0.9	6.48+0.6	5.83+0.3	5.55+2.6	2.92-0.5	3.39
Debt-to-Equity	0.16-0.0	0.18+0.0	0.14+0.0	0.12+0.1	0.000.0	0.00
FCF Margin	14.5%+3.2pp	11.3%+3.1pp	8.2%+5.3pp	2.9%-15.4pp	18.3%-0.4pp	18.7%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	49.8%-2.8pp	52.6%-0.4pp	53.0%+0.7pp	52.3%+1.0pp	51.2%-3.5pp	54.8%-0.8pp	55.6%+2.3pp	53.4%
Operating Margin	-17.2%-27.2pp	10.0%-1.8pp	11.8%+7.8pp	4.0%	N/A	9.9%-6.0pp	15.9%+8.6pp	7.3%
Net Margin	103.9%+156.2pp	-52.4%-101.1pp	48.8%+37.8pp	10.9%+118.2pp	-107.2%-207.8pp	100.5%+439.7pp	-339.2%-402.0pp	62.8%
Return on Equity	9.7%+14.7pp	-5.1%-9.5pp	4.5%+3.5pp	1.0%+11.9pp	-10.9%-19.6pp	8.7%+40.7pp	-31.9%-36.2pp	4.2%
Return on Assets	6.8%+10.3pp	-3.5%-6.6pp	3.1%+2.4pp	0.7%+8.3pp	-7.6%-13.8pp	6.2%+28.5pp	-22.4%-25.4pp	3.0%
Current Ratio	5.62+0.2	5.44+0.3	5.12-0.9	5.99-0.5	6.48+0.3	6.14-0.1	6.28-0.3	6.57
Debt-to-Equity	0.16-0.0	0.180.0	0.17-0.0	0.180.0	0.18+0.0	0.16-0.0	0.18+0.0	0.13
FCF Margin	17.2%+3.5pp	13.7%+2.8pp	10.9%-5.4pp	16.3%+4.1pp	12.2%-6.8pp	19.0%+10.3pp	8.7%+3.8pp	4.9%

Similar Companies

Globus Med Inc GMED

$11.3B

Masimo Corp MASI

$9.3B

Bruker Corp BRKR

$5.2B

iRhythm Holdings, Inc IRTC

$3.7B

Glaukos Corp GKOS

$6.1B

Frequently Asked Questions

What is Bio Rad Labs Inc's annual revenue?

Bio Rad Labs Inc (BIO) reported $2.6B in total revenue for fiscal year 2025. This represents a 0.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio Rad Labs Inc's revenue growing?

Bio Rad Labs Inc (BIO) revenue grew by 0.7% year-over-year, from $2.6B to $2.6B in fiscal year 2025.

Is Bio Rad Labs Inc profitable?

Yes, Bio Rad Labs Inc (BIO) reported a net income of $759.9M in fiscal year 2025, with a net profit margin of 29.4%.

What is Bio Rad Labs Inc's EBITDA?

Bio Rad Labs Inc (BIO) had EBITDA of $212.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bio Rad Labs Inc have?

As of fiscal year 2025, Bio Rad Labs Inc (BIO) had $529.8M in cash and equivalents against $1.2B in long-term debt.

What is Bio Rad Labs Inc's gross margin?

Bio Rad Labs Inc (BIO) had a gross margin of 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bio Rad Labs Inc's operating margin?

Bio Rad Labs Inc (BIO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio Rad Labs Inc's net profit margin?

Bio Rad Labs Inc (BIO) had a net profit margin of 29.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bio Rad Labs Inc's return on equity (ROE)?

Bio Rad Labs Inc (BIO) has a return on equity of 10.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bio Rad Labs Inc's free cash flow?

Bio Rad Labs Inc (BIO) generated $374.6M in free cash flow during fiscal year 2025. This represents a 29.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bio Rad Labs Inc's operating cash flow?

Bio Rad Labs Inc (BIO) generated $532.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bio Rad Labs Inc's total assets?

Bio Rad Labs Inc (BIO) had $10.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bio Rad Labs Inc's capital expenditures?

Bio Rad Labs Inc (BIO) invested $157.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bio Rad Labs Inc spend on research and development?

Bio Rad Labs Inc (BIO) invested $275.6M in research and development during fiscal year 2025.

Does Bio Rad Labs Inc buy back shares?

Yes, Bio Rad Labs Inc (BIO) spent $295.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Bio Rad Labs Inc's current ratio?

Bio Rad Labs Inc (BIO) had a current ratio of 5.62 as of fiscal year 2025, which is generally considered healthy.

What is Bio Rad Labs Inc's debt-to-equity ratio?

Bio Rad Labs Inc (BIO) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio Rad Labs Inc's return on assets (ROA)?

Bio Rad Labs Inc (BIO) had a return on assets of 7.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bio Rad Labs Inc's Altman Z-Score?

Bio Rad Labs Inc (BIO) has an Altman Z-Score of 3.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bio Rad Labs Inc's Piotroski F-Score?

Bio Rad Labs Inc (BIO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio Rad Labs Inc's earnings high quality?

Bio Rad Labs Inc (BIO) has an earnings quality ratio of 0.70x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio Rad Labs Inc cover its interest payments?

Bio Rad Labs Inc (BIO) has an interest coverage ratio of 1.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bio Rad Labs Inc?

Bio Rad Labs Inc (BIO) scores 59 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.